Drugs / BS HH 002.SA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04743115 | Feb 2021 → Feb 2025 | acute myeloid leukemia | Shanghai Bensen Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BS HH 002.SA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04743115 ↗ |
| Route | Subcutaneous | “The dose will be administered subcutaneously once daily on Days 1 through 6 and on Days 10 through 15 of a 28 day cycle.” NCT04743115 ↗ |